795281-92-4

Usage

Uses

Used in Pharmaceutical Industry:
(3R)-3-benzyloxy-1-(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexylpyrrolidine is used as a potential pharmaceutical candidate due to its unique structure and potential biological activity. The presence of the pyrrolidine and cyclohexyl rings, which are often found in biologically active compounds, makes it a promising target for drug development.
Used in Chemical Industry:
(3R)-3-benzyloxy-1-(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexylpyrrolidine is used for further investigation and exploration in the chemical industry. The benzyl and dimethoxyphenyl groups add complexity and the potential for diverse bioactivity, making it a valuable compound for research and development in various chemical applications.

Upstream product

• 867152-08-7 2-(3,4-dimethoxyphenyl)ethyl 2,2,2-trichloroethanimidate 
• 900513-88-4 (1R,2R)-2-[(R)-3-(benzyloxy)pyrrolidin-1-yl]cyclohexanol 

Downstream Products

• 794466-70-9 (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidin-3-ol 
• 748810-28-8 Vernakalant hydrochloride 

Relevant academic research and scientific papers

SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS

Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates and substrates are disclosed.

PRODUCTION METHOD OF OPTICALLY ACTIVE CYCLOHEXANE ETHER COMPOUNDS

The present invention relates to an industrial synthetic method of an optically active cyclohexane ether compound (IIIa) or a salt thereof, which is useful as a pharmaceutical agent, and an intermediate useful for the production method of the present invention. The production method of the present invention is as shown below: wherein each symbol is as defined in the specification. According to the production method of the present invention, efficient and stable supply of an optically active cyclohexane ether compound (IIIa) in a high yield at a lower cost can be afforded. Therefore, an optically active cyclohexane ether compound (IIIa) extremely useful as a pharmaceutical agent can be provided by an industrially highly advantageous method.